| General Information of Drug Metabolite (DM) (ID: DM005665) |
| DM Name |
Sarizotan metabolite M362
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Oxidation - Oxidationn |
EMD-128130
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| EMD-128130 |
DR1872
|
Phase 2/3 |
Rett syndrome |
|
|
| References |
| 1 |
In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
